Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The firm deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The firm operates worldwide.
Follow-Up Questions
Bavarian Nordic A/S 的 CEO 是誰？
Dr. Paul Chaplin 是 Bavarian Nordic A/S 的 President，自 2014 加入公司。
BVNRY 股票的價格表現如何？
BVNRY 的當前價格為 $12.06，在上個交易日 decreased 了 0%。
Bavarian Nordic A/S 的主要業務主題或行業是什麼？
Bavarian Nordic A/S 屬於 Biotechnology 行業，該板塊是 Health Care
